Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.Percepta -- Bioscience questions answered.
bioscience. questions. answered.

In US and Canada Call Toll Free: (877) 597-9236
Everywhere Else Call: (760) 431-6300

Reports

2011 Nucleic Acid Amplification Dashboard Series 3 -

11_pic_nucleic_acid_ampCatalog number: 1109NAA
Publication date: September 2011
Company-wide electronic copy: $3,975

Please enquire about single-user* electronic copy pricing
* single-user pricing is intended for small companies, of 40 or less employees, to access The Life Science Dashboard. Please order these copies directly with Percepta Associates.

 

Overview

Overview

Nucleic acid amplification is one of the most commonly performed molecular biology techniques and is a necessary precursor to a range of methods from gene cloning and site-directed mutagenesis to the quantitative analysis of gene expression. The Nucleic Acid Amplification Dashboard was developed from responses to a 21-question survey by 492 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the nucleic acid amplification market as a whole as well as for the following sub-segments:

  • Difficult PCR (e.g. GC rich, complex, long targets)
  • Digital PCR
  • Emulsion PCR
  • Fast PCR
  • High Fidelity PCR
  • High Resolution Melt (using real time PCR instrument)
  • Standard endpoint PCR
  • Standard endpoint RT-PCR
  • qPCR (real time PCR with genomic DNA template)
  • qRT-PCR (real time PCR with RNA or cDNA template)

While standard protocols may be well-defined, amplification markets are quite fluid, with significant influence from such external sources as:

  • An evolving intellectual property landscape
  • New pricing strategies from established suppliers
  • Application to emerging research areas such as gene silencing, SNP genotyping and rapid, whole genome sequencing

In order to dive more deeply into the characteristics and dynamics of the market for nucleic acid amplification products, Percepta has introduced the Nucleic Acid Amplification Dashboard, designed to take a snapshot of the current market landscape with the future goal of repeating and publishing the study to give Dashboard readers the ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

Survey Methodology

In July of 2011, Percepta fielded the Nucleic Acid Amplification Survey to a subset of the Percepta BioAnalytix™ Panel of life scientists. Individuals were invited by e-mail blast to click-through to a webpage at perceptabioanalytix.com where the survey was hosted. Invitations were delivered beginning on July 22, 2011 and results collected through August 3, 2011. A total of 492 scientists participated in the survey, of which 477 are actively engaged in performing nucleic acid amplification and 6 plan to use nucleic acid amplification methods in the next 12 months. Results based on the aggregate of collected responses are revealed in this Nucleic Acid Amplification Dashboard.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with 18.9% of respondents employed in an industry setting. 71.7% of respondents are from North America, while 26.7% reside in Europe.

Junior (Lab Technician, Graduate Student), mid-level (Post-Doctoral Fellow, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Professor/PI/Instructor (21.3% of respondents), Scientist/Senior Scientist (18.9% of respondents) and Post-Doctoral Fellow/Research Fellow (17.3% of respondents).

A wide variety of scientific areas of specialization is also evident, led by cell biology (named by 18.3% of respondents as their primary area of expertise), followed by biochemistry (15.9%) and microbiology/infectious disease/virology (12.0%).

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 55.3% of respondents work in labs where 1 to 5 people perform nucleic acid amplification experiments at least a few times each year; 37.6% in labs with 6 to 20 experimenters, and the remaining 7.1% in labs with greater than 20 bench scientists.

Table of contents

Table of Contents

  • 6 Figures and Tables
  • 10 Executive Summary
  • 12 Key Findings and Implications
  • 15 Nucleic Acid Amplification Dashboard
  • 18 Nucleic Acid Amplification Market Opportunity Matrix
  • 21 Survey Methodology
  • 23 Survey Invitation Text
  • 24 Respondent Demographics
  • 36 Frequency of Performance of Life Science Techniques
  • 41 Frequency of Performance of Nucleic Acid Amplification
  • 63 Reaction Throughput and Market Growth Rates
  • 72 Respondents’ Stated Price per Reaction
  • 76 Total Market Size, Market Segment Sizes and Total Market Growth Rate
  • 78 Market Shares by Segment (Share of Mentions)
  • 133 Customer Satisfaction and Interest in Switching Suppliers
  • 138 Product Features That Influence Purchasing Decisions
  • 142 Primary and Secondary Downstream Applications
  • 182 Desired Changes to Nucleic Acid Amplification Products
  • 191 Survey Questionnaire
  • 202 Appendix

Figures and Tables

  • 26 Figure 1: Respondents’ Place of Employment
  • 28 Figure 2: Respondent’s Location
  • 30 Figure 3: Respondents’ Job Title
  • 32 Figure 4: Respondents’ Areas of Expertise/Specialization
  • 35 Figure 5: Number of Employees in Respondents’ Laboratories
  • 38 Figure 6: Percentage of Respondents Performing Various Techniques at Least a Few Times per Year
  • 43 Figure 7: Percentage of Respondents Performing Nucleic Acid Amplification
  • 44 Figure 7A: Change in Percentage of Respondents Performing Nucleic Acid Amplification
  • 46 Figure 8: Percentage of Respondents Performing Various Nucleic Acid Amplification Techniques at least a Few Times per Year
  • 47 Figure 9: Percentage of Respondents Using Various Thermostable Polymerases for Nucleic Acid Amplification Techniques
  • 49 Figure 10: Percentage of Respondents Performing Difficult PCR
  • 50 Figure 11: Percentage of Respondents Performing Digital PCR
  • 51 Figure 12: Percentage of Respondents Performing Emulsion PCR
  • 52 Figure 13: Percentage of Respondents Performing Fast PCR
  • 53 Figure 14: Percentage of Respondents Performing High Fidelity PCR
  • 54 Figure 14A: Change in Percentage of Respondents Performing High Fidelity PCR
  • 55 Figure 15: Percentage of Respondents Performing High Resolution Melt
  • 56 Figure 16: Percentage of Respondents Performing Standard Endpoint PCR
  • 57 Figure 17: Percentage of Respondents Performing Standard Endpoint RT-PCR
  • 58 Figure 18: Percentage of Respondents Performing qPCR
  • 59 Figure 19: Percentage of Respondents Performing qRT-PCR
  • 80 Figure 20: Respondents’ Primary Supplier for Difficult PCR
  • 84 Figure 21: Respondents’ Primary Supplier for Digital PCR
  • 88 Figure 22: Respondents’ Primary Supplier for Emulsion PCR
  • 92 Figure 23: Respondents’ Primary Supplier for Fast PCR
  • 96 Figure 24: Respondents’ Primary Supplier for High Fidelity PCR
  • 98 Figure 24A: Change in Mention for Respondents’ Primary Supplier for High Fidelity PCR
  • 101 Figure 25: Respondents’ Primary Supplier for High Resolution Melt
  • 105 Figure 26: Respondents’ Primary Supplier for Standard Endpoint PCR
  • 109 Figure 27: Respondents’ Primary Supplier for Standard Endpoint RT-PCR
  • 113 Figure 28: Respondents’ Primary Supplier for qPCR
  • 117 Figure 29: Respondents’ Primary Supplier for qRT-PCR
  • 123 Figure 30: Respondents’ Primary Supplier of Instruments for Standard PCR
  • 126 Figure 30A: Change in Respondents’ Primary Supplier of Instruments for Standard PCR
  • 128 Figure 31: Respondents’ Primary Supplier of Instruments for Real Time PCR
  • 130 Figure 31A: Change in Respondents’ Primary Supplier of Instruments for Real Time PCR
  • 144 Figure 32: Respondents’ Primary and Secondary Applications for End Products from Difficult PCR
  • 148 Figure 33: Respondents’ Primary and Secondary Applications for End Products from Digital PCR
  • 151 Figure 34: Respondents’ Primary and Secondary Applications for End Products from Emulsion PCR
  • 154 Figure 35: Respondents’ Primary and Secondary Applications for End Products from Fast PCR
  • 158 Figure 36: Respondents’ Primary and Secondary Applications for End Products from High Fidelity PCR
  • 162 Figure 37: Respondents’ Primary and Secondary Applications for End Products from High Resolution Melt
  • 166 Figure 38: Respondents’ Primary and Secondary Applications for End Products from Standard Endpoint PCR
  • 170 Figure 39: Respondents’ Primary and Secondary Applications for End Products from Standard Endpoint RT-PCR
  • 174 Figure 40: Respondents’ Primary and Secondary Applications for End Products from qPCR
  • 178 Figure 41: Respondents’ Primary and Secondary Applications for End Products from qRT-PCR
  • 204 Figure 42: Non-current users of Nucleic Acid Amplification Products – Future Plans

List of Tables

  • 33 Table 1: Respondents’ Area of Expertise (Values for Figure 4)
  • 39 Table 2: Frequency of Performance of Various Life Science Techniques
  • 40 Table 3: Frequency of Co-Performance of Various Life Science Techniques
  • 45 Table 4: Percentage of Respondents Performing Nucleic Acid Amplification by Place of Employment and Location
  • 48 Table 5: Frequency of Performance of Various Nucleic Acid Amplification Techniques
  • 61 Table 6: Frequency of Co-Performance of Life Science Techniques with Nucleic Acid Amplification Techniques
  • 62 Table 7: Frequency of Co-Performance of Nucleic Acid Amplification Techniques with Life Science Techniques
  • 65 Table 8: Mean, Median and Trim Mean Monthly Throughput for Nucleic Acid Amplification Techniques
  • 66 Table 8A: Change in Median Monthly Throughput for Nucleic Acid Amplification Methods – Comparison to the 2009 Dashboard
  • 67 Table 8B: Mean, Median and Trim Mean Monthly Throughput for Nucleic Acid Amplification Methods by Organization Type
  • 68 Table 9: Percentage of Respondents Performing Probe-based vs. DNA inding-dye based Reactions for real time PCR
  • 69 Table 10: Percentage of Respondents Performing Various Numbers of Amplification Reactions Per Month by Product Category
  • 71 Table 11: Projected Growth in the Performance of Various Nucleic Acid Amplification Techniques
  • 74 Table 12: Mean, Median and Trim Mean Price per Reaction for Nucleic Acid Amplification Techniques
  • 75 Table 13: Change in Mean, Median and Trim Mean Price per Reaction for Nucleic Acid Amplification Techniques
  • 77 Table 14: Estimated 2012 Global Market Size for Nucleic Acid Amplification Techniques
  • 82 Table 15: Respondents’ Primary Supplier for Difficult PCR by Market Segment
  • 86 Table 16: Respondents’ Primary Supplier for Digital PCR by Market Segment
  • 90 Table 17: Respondents’ Primary Supplier for Emulsion PCR by Market Segment
  • 94 Table 18: Respondents’ Primary Supplier for Fast PCR by Market Segment
  • 99 Table 19: Respondents’ Primary Supplier for High Fidelity PCR by Market Segment
  • 103 Table 20: Respondents’ Primary Supplier for High Resolution Melt by Market Segment
  • 107 Table 21: Respondents’ Primary Supplier for Standard Endpoint PCR by Market Segment
  • 111 Table 22: Respondents’ Primary Supplier for Standard Endpoint RT-PCR by Market Segment
  • 115 Table 23: Respondents’ Primary Supplier for qPCR by Market Segment
  • 119 Table 24: Respondents’ Primary Supplier for qRT-PCR by Market Segment
  • 120 Table 25: Market Share Leaders for Nucleic Acid Amplification Products
  • 125 Table 26: Respondents’ Primary Supplier of Standard PCR Thermocyclers by Market Segment
  • 131 Table 27: Respondents’ Primary Supplier for Instruments for Real Time PCR by Market Segment
  • 132 Table 28: Market Share Leaders for Standard and Real Time PCR Instruments
  • 135 Table 29: Percentage of Respondents Satisfied with Various Nucleic Acid Amplification Techniques and Reasons for Dissatisfaction
  • 137 Table 30: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
  • 140 Table 31: Most Important Features of Nucleic Acid Amplification Products
  • 141 Table 31A: Most Important Features of Nucleic Acid Amplification Products – Comparison to 2009 Nucleic Acid Amplification Dashboard
  • 145 Table 32: Respondents’ Primary and Secondary Applications for End Products from Difficult PCR (Values for Figure 32)
  • 149 Table 33: Respondents’ Primary and Secondary Applications for End Products from Digital PCR (Values for Figure 33)
  • 152 Table 34: Respondents’ Primary and Secondary Applications for End Products from Emulsion PCR (Values for Figure 34)
  • 155 Table 35: Respondents’ Primary and Secondary Applications for End Products from Fast PCR (Values for Figure 35)
  • 160 Table 36: Respondents’ Primary and Secondary Applications for End Products from High Fidelity PCR (Values for Figure 36)
  • 163 Table 37: Respondents’ Primary and Secondary Applications for End Products from High Resolution Melt (Values for Figure 37)
  • 167 Table 38: Respondents’ Primary and Secondary Applications for End Products from Standard Endpoint PCR (Values for Figure 38)
  • 171 Table 39: Respondents’ Primary and Secondary Applications for End Products from Standard Endpoint RT-PCR (Values for Figure 39)
  • 175 Table 40: Respondents’ Primary and Secondary Applications for End Products from qPCR (Values for Figure 40)
  • 179 Table 41: Respondents’ Primary and Secondary Applications for End Products from qRT-PCR (Values for Figure 41)
  • 181 Table 42: Respondents’ Primary Applications for End Products from Nucleic Acid Amplification

Questionnaire

Available upon request

Copyright © 2017 Percepta Associates Inc. All rights reserved. Terms & Conditions.Designed by Audacity